On August 11, 2026, the Centers for Medicare & Medicaid Services issued a first-of-its-kind final rule barring federal Medicaid and CHIP dollars from covering puberty blockers, cross-sex hormones, or surgeries for minors, effective October 13, 2026. A new analysis from Inspire Investing frames the rule as the capstone of a four-year reversal across American law, medicine, and corporate benefit plans.
The piece, by Chris Hubbard with Tim Schwarzenberger, traces how a once-expanding consensus fractured, in the courts, in the medical literature, in Europe, and in corporate boardrooms, and why values-driven investors are now pressing companies on the issue.
The Supreme Court’s June 2025 ruling in United States v. Skrmetti upheld state limits, leaving bans in roughly 27 states in force. A May 2025 HHS evidence review found the certainty of benefit “very low,” echoing England’s Cass Review.
Corporate participation in the Human Rights Campaign’s Corporate Equality Index fell 65% in a single year, from 377 Fortune 500 companies to 131.
1792 Exchange has named 550-plus companies whose plans still cover these procedures for minor dependents and wrote to 568 companies in June urging them to exclude transgender drugs and surgeries for children.
Inspire organized a coalition representing more than $100 billion in assets, identified 242 companies whose policies may expose shareholders to risk, and presented a shareholder proposal at Nike. Charles Schwab and Walmart have since confirmed their plans exclude these procedures for minors.
The full article can be found at Inspire Investing.